Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study

BMC Nephrology

Volumn 8, Issue , 2007, Pages

  Serra, Andreas L ^a   Kistler, Andreas D ^a   Poster, Diane ^a   Struker, Marian ^a   Wüthrich, Rudolf P ^a   Weishaupt, Dominik ^a   Tschirch, Frank ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; KIDNEY DEVELOPMENT; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PATIENT COMPLIANCE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ADOLESCENT; FEASIBILITY STUDY; PILOT STUDY;

ADOLESCENT; ADULT; FEASIBILITY STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PILOT PROJECTS; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; SIROLIMUS; TREATMENT OUTCOME;

EID: 35748948350     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-8-13     Document Type: Article

References (19)

1. Bilateral polycystic disease of the kidneys; a follow-up of two hundred and eighty-four patients and their families. OZ Dalgaard, Acta Med Scand Suppl 1957 328 1 255 13469269
2. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. N Hateboer MA v Dijk N Bogdanova E Coto AK Saggar-Malik JL San Millan R Torra M Breuning D Ravine, Lancet 1999 353 9147 103 107 10.1016/S0140-6736(98)03495-3 10023895
3. Polycystic kidney disease. PD Wilson, N Engl J Med 2004 350 2 151 164 10.1056/NEJMra022161 14711914
4. Molecular genetics of autosomal recessive polycystic kidney disease. PC Harris S Rossetti, Mol Genet Metab 2004 81 2 75 85 10.1016/j.ymgme.2003.10.010 14741187
5. Linkage, clinical features, and prognosis of autosomal dominant polycystic kidney disease types 1 and 2. R Torra C Badenas A Darnell C Nicolau V Volpini L Revert X Estivill, J Am Soc Nephrol 1996 7 10 2142 2151 8915974
6. Rate of functional deterioration in polycystic kidney disease. KA Franz FC Reubi, Kidney Int 1983 23 3 526 529 10.1038/ki.1983.51 6405076
7. Volume progression in polycystic kidney disease. JJ Grantham VE Torres AB Chapman LM Guay-Woodford KT Bae BF King Jr. LH Wetzel DA Baumgarten PJ Kenney PC Harris S Klahr WM Bennett GN Hirschman CM Meyers X Zhang F Zhu JP Miller, N Engl J Med 2006 354 20 2122 2130 10.1056/NEJMoa054341 16707749
8. Volume of polycystic kidneys during reduction of renal function. HS Thomsen JK Madsen JH Thaysen K Damgaard-Petersen, Urol Radiol 1981 3 2 85 89 7314325
9. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. P Ruggenenti A Remuzzi P Ondei G Fasolini L Antiga B Ene-Iordache G Remuzzi FH Epstein, Kidney Int 2005 68 1 206 216 10.1111/j.1523-1755.2005.00395.x 15954910
10. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. MC Morice PW Serruys JE Sousa J Fajadet E Ban Hayashi M Perin A Colombo G Schuler P Barragan G Guagliumi F Molnar R Falotico, N Engl J Med 2002 346 23 1773 1780 10.1056/NEJMoa012843 12050336
11. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. G Stallone A Schena B Infante S Di Paolo A Loverre G Maggio E Ranieri L Gesualdo FP Schena G Grandaliano, N Engl J Med 2005 352 13 1317 1323 10.1056/NEJMoa042831 15800227
12. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). PR Wahl AL Serra M Le Hir KD Molle MN Hall RP Wuthrich, Nephrol Dial Transplant 2006 21 3 598 604 10.1093/ndt/gfi181 16221708
13. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. M Wu PR Wahl M Le Hir Y Waeckerle-Men RP Wuthrich AL Serra, Kidney Blood Press Res. 2007 30 4 253 259 10.1159/000104818 17596700
14. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. Y Tao J Kim RW Schrier CL Edelstein, J Am Soc Nephrol 2005 16 1 46 51 10.1681/ASN.2004080660 15563559
15. From the Cover: The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. JM Shillingford NS Murcia CH Larson SH Low R Hedgepeth N Brown CA Flask AC Novick DA Goldfarb A Kramer-Zucker G Walz KB Piontek GG Germino T Weimbs, Proc Natl Acad Sci U S A 2006 103 14 5466 5471 16567633 10.1073/pnas.0509694103
16. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. KC Farmer, Clin Ther 1999 21 6 1074 90; discussion 1073 10.1016/S0149-2918(99)80026-5 10440628
17. Adherence to medication. L Osterberg T Blaschke, N Engl J Med 2005 353 5 487 497 10.1056/NEJMra050100 16079372
18. SUISSE ADPKD Study. http://www.ADPKD.ch
19. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. D Ravine RN Gibson RG Walker LJ Sheffield P Kincaid-Smith DM Danks, Lancet 1994 343 8901 824 827 10.1016/S0140-6736(94) 92026-5 7908078